DE50210317D1 - Peptid zur diagnose und therapie der alzheimer-demenz - Google Patents

Peptid zur diagnose und therapie der alzheimer-demenz

Info

Publication number
DE50210317D1
DE50210317D1 DE50210317T DE50210317T DE50210317D1 DE 50210317 D1 DE50210317 D1 DE 50210317D1 DE 50210317 T DE50210317 T DE 50210317T DE 50210317 T DE50210317 T DE 50210317T DE 50210317 D1 DE50210317 D1 DE 50210317D1
Authority
DE
Germany
Prior art keywords
alzheimer
diagnosis
therapy
peptide
demenz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE50210317T
Other languages
English (en)
Inventor
Dieter Willbold
Katja Wiesehan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEIBNIZ INST fur ALTERSFORSCH
Original Assignee
LEIBNIZ INST fur ALTERSFORSCH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEIBNIZ INST fur ALTERSFORSCH filed Critical LEIBNIZ INST fur ALTERSFORSCH
Application granted granted Critical
Publication of DE50210317D1 publication Critical patent/DE50210317D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE50210317T 2001-04-06 2002-04-08 Peptid zur diagnose und therapie der alzheimer-demenz Expired - Lifetime DE50210317D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10117281A DE10117281A1 (de) 2001-04-06 2001-04-06 Peptid zur Diagnose und Therapie der Alzheimer-Demenz
PCT/EP2002/003862 WO2002081505A2 (de) 2001-04-06 2002-04-08 Peptid zur diagnose und therapie der alzheimer-demenz

Publications (1)

Publication Number Publication Date
DE50210317D1 true DE50210317D1 (de) 2007-07-26

Family

ID=7680694

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10117281A Ceased DE10117281A1 (de) 2001-04-06 2001-04-06 Peptid zur Diagnose und Therapie der Alzheimer-Demenz
DE50210317T Expired - Lifetime DE50210317D1 (de) 2001-04-06 2002-04-08 Peptid zur diagnose und therapie der alzheimer-demenz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10117281A Ceased DE10117281A1 (de) 2001-04-06 2001-04-06 Peptid zur Diagnose und Therapie der Alzheimer-Demenz

Country Status (6)

Country Link
EP (1) EP1379546B1 (de)
AT (1) ATE364623T1 (de)
DE (2) DE10117281A1 (de)
ES (1) ES2289110T3 (de)
HK (1) HK1063188A1 (de)
WO (1) WO2002081505A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7635681B2 (en) * 2002-01-09 2009-12-22 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
DE102010019336A1 (de) 2010-05-05 2011-11-10 Forschungszentrum Jülich GmbH Mittel zur Behandlung der Alzheimerschen Demenz
DE102010017130B4 (de) 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
DE102012108598A1 (de) 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
ES2938886T3 (es) 2012-04-05 2023-04-17 Priavoid Gmbh Procedimiento para el tratamiento de sangre, productos sanguíneos y órganos
DE102012102998B4 (de) 2012-04-05 2013-12-05 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung
CN107652356A (zh) * 2012-04-05 2018-02-02 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
DE102012102999A1 (de) * 2012-04-05 2013-10-10 Forschungszentrum Jülich GmbH Verfahren zur Behandlung von Blut, Blutprodukten und Organen
DE102012108599B4 (de) 2012-09-14 2023-06-01 Priavoid Gmbh A-Beta-Oligomer-bindende Peptide und deren Verwendung
DE102012019882A1 (de) * 2012-10-05 2014-04-10 Forschungszentrum Jülich GmbH Peptide zur Behandlung und Frühdiagnose von Morbus Alzheimer und anderer Tauopathien
DE102012022013A1 (de) 2012-11-02 2014-05-08 Forschungszentrum Jülich GmbH Fachbereich Patente Peptide, die an amino-terminal verkürztes Amyloid-beta-Peptid binden und deren Verwendung
DE102013007405A1 (de) * 2013-04-30 2014-11-13 Forschungszentrum Jülich GmbH Agenzien zur Prävention und Therapie von HIV und anderer viraler Infektionen
DE102013016002A1 (de) 2013-09-26 2015-03-26 Forschungszentrum Jülich GmbH Zyklische, Amyloid-Beta-bindende Peptide und deren Verwendung
DK2991664T3 (da) 2013-04-30 2019-12-02 Forschungszentrum Juelich Gmbh Midler til forebyggelse og behandling af følgesygdomme af HIV og andre virusinfektioner
DE102014003262A1 (de) 2014-03-12 2015-09-17 Forschungszentrum Jülich GmbH Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
JP2016523274A (ja) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用
DK3049099T3 (da) 2013-09-26 2020-09-21 Priavoid Gmbh Amyloid-beta-bindende peptider og anvendelse deraf til terapi og diagnosticering af alzheimers demens
DE102015003676A1 (de) 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
DE102015003503A1 (de) 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Spezifisch Amyloid-Beta bindende Peptide und deren Verwendung für die Therapie und Diagnose der Alzheimerschen Demenz
DE102016125645A1 (de) 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6420110B1 (en) * 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
WO2000052048A1 (en) * 1999-03-04 2000-09-08 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
GB9917725D0 (en) * 1999-07-28 1999-09-29 Medical Res Council Peptides

Also Published As

Publication number Publication date
WO2002081505A3 (de) 2003-10-23
EP1379546A2 (de) 2004-01-14
WO2002081505A2 (de) 2002-10-17
HK1063188A1 (en) 2004-12-17
EP1379546B1 (de) 2007-06-13
ES2289110T3 (es) 2008-02-01
DE10117281A1 (de) 2002-10-24
ATE364623T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
DE50210317D1 (de) Peptid zur diagnose und therapie der alzheimer-demenz
IL203894A (en) Use of a polypeptide to prepare a drug to induce angiogenesis or liver regeneration
MY148086A (en) Antibodies directed against amyloid-beta peptide and methods using same
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
ATE386538T1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
ATE346303T1 (de) Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden
WO2000078344A8 (en) Prion protein peptides and uses thereof
AU6160201A (en) Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
CA2268029A1 (en) Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
GEP20043386B (en) β -Amyloid Peptide-Binding Proteins and Polynucleotides Encoding the Same
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
MY140828A (en) Therapeutic uses of tri-, tetra-, penta-, and polypeptides
ATE306497T1 (de) Peptid für die diagnose und therapie von tumoren
ATE230027T1 (de) Menschliche dnase i varianten
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
WO2003033675A3 (en) Identification of binding partners for specific proteins
AU2003286530A8 (en) Substituted peptides useful in the treatment of alzheimer's disease
WO2002100897A3 (fr) Complexes moleculaires brca1/acc alpha, applications diagnostiques et therapeutiques
Critical Care Society of South Africa Working Group Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)
AU2002312797A1 (en) Peptide for the diagnosis and therapy of alzheimer's disease
WO2002062955A3 (en) Dendritic enriched secreted lymphocyte activation molecule
WO2001075041A3 (fr) Nouveau polypeptide, proteine humaine associee a l'epilepsie 11, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition